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Application of nested polymerase chain reaction
and serology for diagnosis of Chlamydophila
pneumoniae in pediatric community-acquired
lower respiratory tract infections
S. Kumar, S.R. Saigal, G.R. Sethi
Maulana Azad Medical College, New Delhi, New
Delhi, India
Background: Chlamydophila pneumoniae (C. pneumoniae)is a
common cause of community-acquired respiratory infections,
including pneumonia, bronchitis and upper respiratory tract infec-
tions. C. pneumoniae is responsible for 6-20% of all community
acquired pneumonias. The detection of antibodies in paired serum
samples has been considered the standard laboratory diagnostic
method, but polymerase chain reaction (PCR) is considered to be
a more reliable diagnostic method than other techniques for the
laboratory diagnosis of C. pneumoniae. The aim of this study was to
detectC pneumoniae infections in Indian childrenwith community-
acquired lower respiratory tract infections (LTRIs) using nested PCR
and serology.
Methods & Materials: We studied 150 children aged 2 months-
12 years who were hospitalized for community-acquired lower
respiratory tract infections (LRTIs). Paired serum samples were
obtained on admission and after 4–6 weeks to assay the titers of
C. pneumoniae antibodies by enzyme linked immunosorbent assay
(ELISA). Nasopharyngeal aspirates were obtained on admission for
analysis of Chlamydophila pneumoniaeby nested polymerase chain
reaction (PCR).
Results:A total of 150 childrenwere enrolled: 72 (48%) children
were of age2-6months, 56 (37.3%) 7-12months, 8(5.3%) 13months
to 24months 10 (6.7%) 25-60months and 4 (2.6%) 5-12 years. Clini-
cal and radiological features in C pneumoniae positive and negative
groups were comparable. None of the signs, symptoms, or labora-
tory parameters considered in this study seem to be unique to C.
pneumoniae infection. Radiological features in C. pneumoniae pos-
itive and C. pneumoniae negative cases were comparable and no
feature was signiﬁcantly associated with a positive C. pneumoniae
ﬁnding. Nineteen (12.7%) specimenswere serologically positive for
C. pneumoniae and 7(4.7%) NPA specimens documented positive
nested PCR for C pneumoniae; 6(85.7%) serologically proven and
1 (14.3%) serologically unproven C.pneumoniae infection. Together
20(13.3%) specimens were positive by serology and/or nested PCR
for C.pneumoniae infection.
Conclusion: In conclusion, our study conﬁrms that C.
pneumoniae plays a signiﬁcant role in Indian children with
community-acquired LRTIs, even in children aged<5years. Nested
PCR supported by serology may be useful for diagnosis of C. pneu-
moniae in paediatric LRTIs.
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In vitro antibacterial activity of beta
lactam-beta lactamase inhibitor combinations
against clinical Isolates of acinetobacter
F. Rasheed
Combined Military Hospital, Lahore, Pakistan,
Lahore, Pakistan
Background:Acinetobacter has emerged as an important noso-
comial pathogen that is capable of causing infectious outbreaks
in critically ill patients. Acinetobacter is rated among top seven
pathogens that disturb the health care delivery system because
of its capability to acquire diverse resistance mechanisms. This
has resulted in the emergence of multidrug resistant and pan
drug resistant strains. The use of beta-lactamase inhibitors in
combinationwithbeta-lactamantibiotics is currently themost suc-
cessful strategy to combat a speciﬁc resistance mechanism. Their
broad spectrum of activity originates from the ability of respective
inhibitors to inactivate a wide range of beta-lactamases produced
by Gram positive, Gram negative and even acid-fast pathogens.We
evaluated 5 different combinations of beta lactam- beta lactamase
inhibitor against multi drug resistant clinical isolate of Acinetobac-
ter.
Methods & Materials: A total of 100 clinical isolate of Acine-
tobacter were were evaluated against ﬁve combinations of beta
lactam – beta lactamase inhibitor combinations by Modiﬁed Kirby
Bauer disc diffusion method using Mueller-Hinton agar. Zone sizes
were interpreted according to CLSI 2013 guidelines.
Results: Out of 100 isolates, 85 were of Acinetobacter bauman-
nii, 9 were of Acinetobacter johnsonii, 6 were of Acinetobacter lwofﬁi.
84 isolates of Acinetobacter baumannii, 8 isolates of Acinetobac-
ter johnsonii, and all 6 isolates of Acinetobacter lwofﬁi were multi
drug resistant. One isolate from each Acinetobacter baumanni and
Acinetobacter johnsonii, and no isolate of Acinetobacter lwofﬁi were
susceptible toAmoxicillin-clavulanic acid. 28 isolates ofAcinetobac-
ter baumanni, one isolate of Acinetobacter johnsonii, and no isolate
of Acinetobacter lwofﬁi were susceptible toAmpicillin-sulbactam.
41 isolates of Acinetobacter baumanni, one isolate of Acinetobacter
johnsonii, and no isolate of Acinetobacter lwofﬁi were susceptible
toPiperacillin-sulbactam. 8 isolates of Acinetobacter baumanni, one
isolate of Acinetobacter johnsonii, and no isolate of Acinetobacter
lwofﬁi were susceptible toPiperacillin-tazobactam.48 isolates of
Acinetobacter baumannii, one isolate of Acinetobacter johnsonii, and
no isolate of Acinetobacter lwofﬁiwere susceptible toCefaperazone-
sulbactam.
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